does FLGR242 have a 19-day half-life?

the seller describes a construct and a 19-day half-life. those claims are not an independently characterized identity or a compound-specific concentration-time study.

verdict: unsupported because identity and PK both fail (identity unresolved / no compound-specific study)

quick answer

the seller claims a 19-day half-life, but no independently verified FLGR242 concentration-time study supporting that number was located. the seller's fragment, linker, approximate-mass and binding descriptions do not independently characterize the complete construct.

the evidence

the seller description does not close the identity gap. (gap)

The seller describes a fragment, linker, approximate mass and binding value. No complete construct or independent characterization package was located under the exact name.

a platform patent is not a product study. (contradicted)

The accessible GLYCLOK application describes a broad albumin-binding platform but does not name FLGR242 or report its pharmacokinetics.

purity does not close the gap. (risk)

A purity percentage cannot establish sequence, modification, folding, activity, sterility, or endotoxin burden. No proxy molecule supplies the missing 19-day number.

bottom line

the seller claim is not compound-specific pharmacokinetic evidence; the 19-day number remains unsupported.

scores

• identity: 0 · no verified sequence or exact structure
• compound PK: 0 · no FLGR242 concentration-time study
• human evidence: 0 · no registered study located
• claim risk: 96 · platform language is being treated as product proof

keep reading

• open FLGR242 entry · full identity-failure record
• open follistatin entry · do not transfer a different molecule's record

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.